Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 1/20 | 0.58 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.47 |
| ▸ | PDE4A | P27815 | 1/20 | 0.47 |
| ▸ | LMNA | P02545 | 1/20 | 0.47 |
| ▸ | SLC6A6 | P31641 | 1/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.47 |
| ▸ | BLM | P54132 | 1/20 | 0.47 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.35 |
| ▸ | CA5A | P35218 | 1/20 | 0.33 |
| ▸ | CA5B | Q9Y2D0 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ethylene SCHEMBL6422088 | 1.00 | APP (0.58) | APPPTGS1PDE4ALMNASLC6A6 | |
| Ethylene SCHEMBL6413213 | 1.00 | APP (0.58) | APPPTGS1PDE4ALMNASLC6A6 | |
| Ethylene SCHEMBL6420680 | 1.00 | APP (0.58) | APPPTGS1PDE4ALMNASLC6A6 | |
| Ethylene SCHEMBL9446237 | 1.00 | APP (0.58) | APPPTGS1PDE4ALMNASLC6A6 | |
| SCHEMBL35183 | 0.93 | APP (0.65) | APPPTGS1PDE4ALMNASLC6A6 | |
| SCHEMBL1270406 | 0.89 | APP (0.61) | APPPTGS1PDE4ALMNASLC6A6 | |
| SCHEMBL922126 | 0.89 | APP (0.61) | APPPTGS1PDE4ALMNASLC6A6 | |
| SCHEMBL1270542 | 0.89 | APP (0.61) | APPPTGS1PDE4ALMNASLC6A6 | |
| SCHEMBL917843 | 0.89 | APP (0.61) | APPPTGS1PDE4ALMNASLC6A6 | |
| SCHEMBL10693026 | 0.89 | APP (0.61) | APPPTGS1PDE4ALMNASLC6A6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1345946-B1 | MACROHETEROCYLIC COMPOUNDS USEFUL AS KINASE INHIBITORS | ORTHO MCNEIL PHARM INC (US) | 2005-08-10 | — | — | EP | disclosed |
| US-6828327-B2 | For therapy of chronic pain, neuropathic pain, epilepsy, chronic neurodegenerative conditions, dementia, Alzheimer's disease, schizophrenia, manic depression, neurotraumatic, cognitive decline and ischemia-related diseases | ORTHO-MCNEIL PHARMACEUTICAL, INC. | 2004-12-07 | — | — | US | disclosed |
| EP-1345946-A1 | MACROHETEROCYLIC COMPOUNDS USEFUL AS KINASE INHIBITORS | Ortho-McNeil Pharmaceutical, Inc. (US) | 2003-09-24 | — | — | EP | disclosed |
| US-20030078280-A1 | Macroheterocylic compounds useful as kinase inhibitors | ORTHO-MCNEIL PHARMACEUTICAL, INC. | 2003-04-24 | — | — | US | disclosed |
| WO-2002046197-A1 | MACROHETEROCYLIC COMPOUNDS USEFUL AS KINASE INHIBITORS | ORTHO-MCNEIL PHARMACEUTICAL, INC. (US) | 2002-06-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030078280-A1 | Macroheterocylic compounds useful as kinase inhibitors | PRKCH, MAP3K6, MAP3K2 | APP 4323/4885PTGS1 3723/4885PDE4A 2182/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.